Novel Intravesical Therapeutics In the Treatment of Non-muscle Invasive Bladder Cancer: Horizon scanning

Overview

Journal Front Surg

Specialty General Surgery

Date 2022 Aug 12

PMID 35959122

Authors

Kelly Ward

Mark O Kitchen

Suresh-Jay Mathias

Farhat L Khanim

Richard T Bryan

Affiliations

Soon will be listed here.

Abstract

Introduction: Non-muscle-invasive bladder cancer (NMIBC) is a common and heterogeneous disease; many patients develop recurrent or progress to muscle-invasive disease. Intravesical drug therapy is a pillar in the current management of NMIBC; notwithstanding, Mitomycin C (MMC) and Bacillus Calmette-Guérin (BCG) have numerous limitations including international supply issues, and local and systemic toxicity. Here we review novel intravesical therapeutic options and drug delivery devices with potential for clinical use in the treatment of NMIBC.

Methods: PubMed, ClinicalTrials.gov and Cochrane Library searches were undertaken. Systematic reviews, meta-analyses, randomised controlled trials, single-arm clinical trials and national/international conference proceedings were included.

Results: Novel intravesical drugs, including chemotherapeutic agents, immune checkpoint inhibitors, monoclonal antibodies and gene therapies, have demonstrated varying efficacy in the treatment of NMIBC. Current evidence for the majority of treatments is mostly limited to single-arm trials in patients with recurrent NMIBC. Various novel methods of drug delivery have also been investigated, with encouraging preliminary results supporting the intravesical delivery of hyperthermic MMC and MMC hydrogel formulations.

Conclusions: Novel therapeutic agents and drug delivery systems will be important in the future intravesical management of NMIBC. As our understanding of the molecular diversity of NMIBC develops, molecular subtyping will become fundamental in the personalisation of intravesical treatments. Further randomised studies are urgently required to investigate the efficacy of novel intravesical treatments and novel regimens, in comparison to current standards-of-care, particularly in the context of international BCG shortages.

Citing Articles

Balancing risks and benefits in the treatment of patients with Bacillus Calmette-Guerin-unresponsive high-risk non-muscle-invasive bladder cancer.

Unsworth-White S, Humayun-Zakaria N, Bryan R Transl Androl Urol. 2025; 14(1):1-3.

PMID: 39974809 PMC: 11833534. DOI: 10.21037/tau-24-529.

Peripheral Mechanisms Underlying Bacillus Calmette-Guerin-Induced Lower Urinary Tract Symptoms (LUTS).

Elmasri M, Clark A, Grundy L Brain Sci. 2025; 14(12.

PMID: 39766402 PMC: 11675006. DOI: 10.3390/brainsci14121203.

Novel Delivery Mechanisms for Existing Systemic Agents and Emerging Therapies in Bladder Cancer.

Zhang J, Starr S, Chamie K Bladder Cancer. 2024; 9(2):109-123.

PMID: 38993290 PMC: 11181680. DOI: 10.3233/BLC-220114.

Local Drug Delivery in Bladder Cancer: Advances of Nano/Micro/Macro-Scale Drug Delivery Systems.

Marchenko I, Trushina D Pharmaceutics. 2023; 15(12).

PMID: 38140065 PMC: 10747982. DOI: 10.3390/pharmaceutics15122724.

References

Powles T, van der Heijden M, Castellano D, Galsky M, Loriot Y, Petrylak D . Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2020; 21(12):1574-1588. DOI: 10.1016/S1470-2045(20)30541-6. View

Mitra A, Birkhahn M, Cote R . p53 and retinoblastoma pathways in bladder cancer. World J Urol. 2007; 25(6):563-71. DOI: 10.1007/s00345-007-0197-0. View

Benedict W, Tao Z, Kim C, Zhang X, Zhou J, Adam L . Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. Mol Ther. 2004; 10(3):525-32. DOI: 10.1016/j.ymthe.2004.05.027. View

Li H, Duymich C, Weisenberger D, Liang G . Genetic and Epigenetic Alterations in Bladder Cancer. Int Neurourol J. 2016; 20(Suppl 2):S84-94. PMC: 5169086. DOI: 10.5213/inj.1632752.376. View

Barlow L, McKiernan J, Benson M . Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy. J Urol. 2012; 189(3):834-9. DOI: 10.1016/j.juro.2012.10.068. View

Schellens J, Planting A, van Acker B, Loos W, de Boer-Dennert M, van der Burg M . Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09. J Natl Cancer Inst. 1994; 86(12):906-12. DOI: 10.1093/jnci/86.12.906. View

Koya M, Simon M, Soloway M . Complications of intravesical therapy for urothelial cancer of the bladder. J Urol. 2006; 175(6):2004-10. DOI: 10.1016/S0022-5347(06)00264-3. View

Lindskrog S, Prip F, Lamy P, Taber A, Groeneveld C, Birkenkamp-Demtroder K . An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. Nat Commun. 2021; 12(1):2301. PMC: 8052448. DOI: 10.1038/s41467-021-22465-w. View

Gardmark T, Carringer M, Beckman E, Malmstrom P . Randomized phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent Stage Ta urothelial cell carcinoma of the bladder. Urology. 2005; 66(3):527-30. DOI: 10.1016/j.urology.2005.03.084. View

10.

Chevli K, Shore N, Trainer A, Smith A, Saltzstein D, Ehrlich Y . Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial. J Urol. 2021; 207(1):61-69. PMC: 8667793. DOI: 10.1097/JU.0000000000002186. View

11.

Wallace D, Bryan R, Dunn J, Begum G, Bathers S . Delay and survival in bladder cancer. BJU Int. 2002; 89(9):868-78. DOI: 10.1046/j.1464-410x.2002.02776.x. View

12.

Zargar H, Aning J, Ischia J, So A, Black P . Optimizing intravesical mitomycin C therapy in non-muscle-invasive bladder cancer. Nat Rev Urol. 2014; 11(4):220-30. DOI: 10.1038/nrurol.2014.52. View

13.

Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M . Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol. 2000; 163(3):761-7. View

14.

Tan W, Panchal A, Buckley L, Devall A, Loubiere L, Pope A . Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus.... Eur Urol. 2018; 75(1):63-71. DOI: 10.1016/j.eururo.2018.09.005. View

15.

Ueno H, Kiyosawa K, Kaniwa N . Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?. Br J Cancer. 2007; 97(2):145-51. PMC: 2360307. DOI: 10.1038/sj.bjc.6603860. View

16.

Hashizume A, Umemoto S, Yokose T, Nakamura Y, Yoshihara M, Shoji K . Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with Bacillus Calmette-Guerin. Oncotarget. 2018; 9(75):34066-34078. PMC: 6183350. DOI: 10.18632/oncotarget.26122. View

17.

McKiernan J, Holder D, Ghandour R, Barlow L, Ahn J, Kates M . Phase II trial of intravesical nanoparticle albumin bound paclitaxel for the treatment of nonmuscle invasive urothelial carcinoma of the bladder after bacillus Calmette-Guérin treatment failure. J Urol. 2014; 192(6):1633-8. DOI: 10.1016/j.juro.2014.06.084. View

18.

Cookson M, Chang S, Lihou C, Li T, Harper S, Lang Z . Use of intravesical valrubicin in clinical practice for treatment of nonmuscle-invasive bladder cancer, including carcinoma in situ of the bladder. Ther Adv Urol. 2014; 6(5):181-91. PMC: 4144261. DOI: 10.1177/1756287214541798. View

19.

Kowalski M, Entwistle J, Cizeau J, Niforos D, Loewen S, Chapman W . A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients. Drug Des Devel Ther. 2010; 4:313-20. PMC: 2998804. DOI: 10.2147/DDDT.S14071. View

20.

Puri R, Palit V, Loadman P, Flannigan M, Shah T, Choudry G . Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer. J Urol. 2006; 176(4 Pt 1):1344-8. DOI: 10.1016/j.juro.2006.06.047. View